IGNITE DMD Phase I/II Clinical Trial Update

Solid Biosciences issued a press release providing new, positive 2-year data from their IGNITE DMD clinical study in advance of the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.

We’re pleased to share this corresponding letter to the Duchenne community which better outlines the significance of the reported two-year interim efficacy and safety data from the first three patients treated with SGT-001 in the high dose cohort as part of IGNITE DMD.

Read the Letter to the Duchenne Community: Data and IGNITE DMD Phase I/II Clinical Trial Update here: https://www.solidbio.com/about/media/news/letter-to-the-duchenne-community-data-and-ignite-dmd-phase-i-ii-clinical-trial-update